Xartemis approval

[Anonymous]

http://www.topix.com/forum/city/glenmont-ny/T6JUQE49IQI2DTCRM

 

[Anonymous]

http://www.topix.com/forum/city/glenmont-ny/T6JUQE49IQI2DTCRM

https://www.google.com/#q=business+wire+xartemis&spell=1

 

[Anonymous]

I can't tell if Xartemis will provide much competition.

 

[Anonymous]

I can't tell if Xartemis will provide much competition.

acute pain indication. this will have a tough time against generic IR opioids. Not much of a threat to ER opioids for chronic pain

 

[Anonymous]

acute pain indication. this will have a tough time against generic IR opioids. Not much of a threat to ER opioids for chronic pain

Keep thinking that. You'll see soon. LMFAO.

 

[Anonymous]

lets not for get Purdue just got their long acting hydrocodone approved as well with TAMPER resistant delivery system. I see the water coming in the boat and its beginning to list.

 

[Anonymous]

Keep thinking that. You'll see soon. LMFAO.

Let the games begin. If you think payers will reimburse Xartemis for chronic pain, think again. If you think payers will reimburse for acute pain management when generics options are available, keep thinking. Eventually you'll think about a little drug called Oxecta, a branded abuse-deterrent oxycodone for acute pain that tanked, and you''ll laugh so hard you'll have a stroke. And when you recover, think about how patients are telling their docs that the 12 hour coverage of Xartemis is really like 8, if you're lucky. Yes, it's very funny. Keep your resume updated.

 

[Anonymous]

not yet. their phase 3 was positive, tho, so approval is not far behind. yes, this is a threat. big time.

 

[Anonymous]

Xartemis is indicated for acute pain, no competition for Zohydro.

 

[Anonymous]

not yet. their phase 3 was positive, tho, so approval is not far behind. yes, this is a threat. big time.

Not really. We have 3 year exclusivity per the FDA Hatchmann Act. Purdue can't get NDA until Oct 2016. Then Purdue would have to challenge the patent, we would sue, and the FDA WOULD HAVE TO grant a 30 MONTH STAY!!!! By then our AD product would be on the street and patent extended. See why Purdue is using their $600 Million per quarter revenue from OxyContin to sink Zogenix!?!??!

 

[Anonymous]

Not really. We have 3 year exclusivity per the FDA Hatchmann Act. Purdue can't get NDA until Oct 2016. Then Purdue would have to challenge the patent, we would sue, and the FDA WOULD HAVE TO grant a 30 MONTH STAY!!!! By then our AD product would be on the street and patent extended. See why Purdue is using their $600 Million per quarter revenue from OxyContin to sink Zogenix!?!??!

Help me out here. So you're saying that because Zogenix has exclusivity due to the Hatchman Act for a non-abuse deterrent ER hydrocodone, then Purdue can't file a different ER formulation? How the heck did about 9 million transmucosal immediate-release fentanyls get approved?